-
Sector Analysis
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7 major markets and provides an Excel-based forecast model for the epilepsy market through 2035. GlobalData anticipates that the global adult epilepsy market will grow steadily during the forecast period, with 7MM sales expected to increase from $11.4 billion in 2025 to $17.8 billion in 2035, at a compound annual growth rate (CAGR) of 4.5%. In 2025, the US contributed approximately $9.2 billion in drug sales, representing 80.4% of the total adult epilepsy market across the...
-
Sector Analysis
Melanoma: Epidemiology Forecast to 2035
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, which is the most superficial layer of the skin (World Health Organization, 2017). Melanoma typically presents as a mole (nevus) on the skin, and is characterized by the growth’s asymmetry, irregular border, color variation, diameter greater than six millimeters, and evolution in appearance over a few weeks or months (Gadeliya Goodson and Grossman, 2009; Goodman and Snyder, 2012). This report focuses on melanoma...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, June 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Track & Monitor
Merger and Acquisition Trends in Pharma - Q2 2026
This report analyzes the merger and acquisition (M&A) activity in Q2 2026 in the Pharma sector.
-
Track & Monitor
Venture Capital Investment Trends in Pharma - Q2 2026
This report analyzes the venture capital (VC) investment activity in Q2 2026 in the Pharma sector.
-
Sector Analysis
Emerging Market Outsourcing Report, Q2 2026
This expert outsourcing report is a comprehensive look at the pharmaceutical manufacturing landscape for emerging markets in Q2 2026, including analysis of news and trends affecting contract manufacturing organizations (CMOs) and the identification of recent contract service agreements, mergers, acquisitions, and financing among CMOs. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the pharmaceutical value chain that will provide insights into API (biologics and chemical) as well as dose manufacturing and...
-
Sector Analysis
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Focal Segmental Glomerulosclerosis (FSGS) Therapeutics. In 2025, there were 37,049 incident cases of FSGS in the 16 countries covered in GlobalData’s epidemiology forecast. In 2021, the most recent guideline for physicians for diagnosis and treatment of FSGS was established across seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan) by the Kidney Disease Improving Global Outcomes (KDIGO). Over roughly the past three years,...
-
Consumer Insights
Industry Insights: How Dietary Supplements Have Evolved Beyond Traditional Health Management
This report highlights the shift in consumer preferences from traditional health supplements to modern formats designed to address specific health needs. As people become more health-conscious, they are increasingly seeking tailored, localized products that support longevity and overall vitality. Growing interest in these contemporary supplements is largely fueled by online marketing and easier access to health information through social media. The report explores consumer interest in nootropics, nutricosmetics, and cellular health supplements. As health and wellness become a higher priority...
-
Sector Analysis
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in IgA Nephropathy (Berger’s Disease) Therapeutics. • In 2025, there were 102,155 incident cases of Berger's disease in the 16 countries covered in GlobalData’s epidemiology forecast. • Berger's disease is primarily managed with blood pressure medication like ACE inhibitors or ARBs to protect the kidneys. For high-risk patients, corticosteroids and newer targeted therapies are also available to slow the disease's progression. • The Berger's disease pipeline holds...
-
Sector Analysis
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics. In 2025, there were 308.98 million 12- month total diagnosed prevalent cases of GERD in the 16 countries covered in GlobalData’s epidemiology forecast. The management of GERD typically includes a mix of lifestyle adjustments, medication-based treatments, and, in certain cases, surgical or procedural options. Key therapy classes showing this effect include PPIs, histamine H2 receptor (HRH2) antagonists, and dopamine receptor...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.